Indisuan Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 19-01-2025
- Paid Up Capital ₹ 1.00 M
as on 19-01-2025
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 79.10%
(FY 2023)
- Profit 4573.80%
(FY 2023)
- Ebitda 436.16%
(FY 2023)
- Net Worth 485.54%
(FY 2023)
- Total Assets 75.62%
(FY 2023)
About Indisuan Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Harsh Pandey and Francisco Saniger serve as directors at the Company.
- CIN/LLPIN
U51909MH2018FTC307297
- Company No.
307297
- Company Classification
Private Limited Foreign Company Incorporated In India
- Incorporation Date
28 Mar 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Indisuan Pharmaceuticals Private Limited offer?
Indisuan Pharmaceuticals Private Limited offers a wide range of products and services, including API (Active Pharmaceutical Ingredients), API Intermediate.
Who are the key members and board of directors at Indisuan Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Harsh Pandey  | Director | 28-Mar-2018 | Current |
Francisco Saniger  | Director | 28-Mar-2018 | Current |
Financial Performance of Indisuan Pharmaceuticals.
Indisuan Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 79.1% increase. The company also saw a substantial improvement in profitability, with a 4573.8% increase in profit. The company's net worth Soared by an impressive increase of 485.54%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Indisuan Pharmaceuticals?
In 2023, Indisuan Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Indisuan Pharmaceuticals?
Indisuan Pharmaceuticals has a workforce of 7 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Indisuan Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Indisuan Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.